Discovery of an inhibitor of DNA-driven inflammation that preferentially targets the AIM2 inflammasome
iScience, ISSN: 2589-0042, Vol: 26, Issue: 5, Page: 106758
2023
- 19Citations
- 21Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations19
- Citation Indexes19
- CrossRef19
- 19
- Captures21
- Readers21
- 21
- Mentions1
- News Mentions1
- 1
Most Recent News
The Role of the AIM2 Gene in Obesity-Related Glucose and Lipid Metabolic Disorders: A Recent Update
Introduction Metabolic diseases are usually caused by abnormalities in the metabolism of certain substances or energy sources in the body, and the underlying mechanisms are
Article Description
Inflammation driven by DNA sensors is now understood to be important to disease pathogenesis. Here, we describe new inhibitors of DNA sensing, primarily of the inflammasome forming sensor AIM2. Biochemistry and molecular modeling has revealed 4-sulfonic calixarenes as potent inhibitors of AIM2 that likely work by binding competitively to the DNA-binding HIN domain. Although less potent, these AIM2 inhibitors also inhibit DNA sensors cGAS and TLR9 demonstrating a broad utility against DNA-driven inflammatory responses. The 4-sulfonic calixarenes inhibited AIM2-dependent post-stroke T cell death, highlighting a proof of concept that the 4-sulfonic calixarenes could be effective at combating post-stroke immunosuppression. By extension, we propose a broad utility against DNA-driven inflammation in disease. Finally, we reveal that the drug suramin, by virtue of its structural similarities, is an inhibitor of DNA-dependent inflammation and propose that suramin could be rapidly repurposed to meet an increasing clinical need.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2589004223008350; http://dx.doi.org/10.1016/j.isci.2023.106758; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85159103797&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37216118; https://linkinghub.elsevier.com/retrieve/pii/S2589004223008350; https://dx.doi.org/10.1016/j.isci.2023.106758
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know